Results 191 to 200 of about 22,015 (248)

Clinical outcomes and drug sustainability after non-medical switch from ustekinumab originator to biosimilars in inflammatory bowel disease. [PDF]

World J Gastroenterol
Kritzinger J, Candel I, Kotrri G, Nadeem H, Afif W, Bitton A, Wild G, Bessissow T, Lakatos PL.   +8 more
europepmc   +1 more source

Immune checkpoint inhibitor-based first-line therapies for advanced or unresectable hepatocellular carcinoma: a network meta-analysis and cost-effectiveness analysis. [PDF]

Ther Adv Med Oncol
Qi H, Huang Y, Zhang W, Li J, Wang T, Ying Y, Chen B, Miao F, Li Q.   +8 more
europepmc   +1 more source

Analytical Physicochemical and Functional Studies to Compare AryoTrust, a Follow-On Biologics, with the Originator Trastuzumab (Herceptin). [PDF]

Pharmaceutics
Al-Kinani KK, Alkufi HK, Taher SS.
europepmc   +1 more source

Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.

JAMA Netw Open
Riegler JS, Kesselheim AS, Rome BN.
europepmc   +1 more source

Short-term outcomes of aflibercept biosimilar SB15 in macular edema secondary to retinal vein occlusion. [PDF]

BMC Ophthalmol
Cho J, Park SM, Kim CG, Kim JH.
europepmc   +1 more source

Evaluation of a New Potential Bevacizumab Biosimilar in Corneal Neovascularization. [PDF]

Turk J Ophthalmol
Özgür A, Yeşilırmak N, İnan MA, Bağrıaçık EÜ, Özmen MC.   +4 more
europepmc   +1 more source

Current status and trends of anti-tumor biosimilars in China from 2019 to 2023: A cross-sectional analysis. [PDF]

Saudi Pharm J
Shan H, Guo Z, Ye X, Du Q, Liu J, Wang M.   +5 more
europepmc   +1 more source

Safety outcomes in 2132 Danish patients with inflammatory arthritis treated with biosimilar infliximab (GP1111) in routine care. [PDF]

Ther Adv Musculoskelet Dis
Nabi H, Jensen KY, Westermann R, Hendricks O, Jensen DV, Loft AG, Just SA, Pedersen JK, Danebod K, Munk HL, Kristensen S, Colic A, Thygesen PH, Ammitzbøll M, Chrysidis S, Mehnert F, Steen Krogh N, Hetland ML, Glintborg B.   +18 more
europepmc   +1 more source

Real-world outcomes of ranibizumab biosimilars in various retinal diseases: a Korean multi-center experience-ROSE Korea Study. [PDF]

Sci Rep
Song JR, Park UC, Lee CS, Cho JJ, Kim JY, Baek SC, Jeong A, Sharma A, Kim JH, Sagong M, Woo SJ, International Retina Biosimilar Study Group (Inter BIOS Group).   +11 more
europepmc   +1 more source

Savings from biosimilars and Medicare formulary access. [PDF]

Health Aff Sch
Axelsen K, Courmier D, Bai G, Maini L.
europepmc   +1 more source